Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
2022年10月11日 - 9:30PM
Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn” or the
“Company”), today announces that it is changing its name to Eterna
Therapeutics Inc. (“Eterna”) to reflect its focus on developing
advanced therapies using its extensively patented in-licensed mRNA
cell engineering technologies. The name change will be effective
Monday, October 17, 2022. The Company’s common stock will trade on
The Nasdaq Global Market under the new ticker symbol “ERNA”. The
new ticker symbol, together with a one-for-twenty consolidation of
the Company’s common stock, will become effective at the open of
the market on October 17, 2022.
“Eterna’s vision is to transform medicine by unlocking the
potential of revolutionary cell engineering technology,” said Matt
Angel, Ph.D., Interim Chief Executive Officer of Brooklyn. “Eterna
is well positioned to build on more than a decade of groundbreaking
research by our technology partner, Factor Bioscience. This
research has resulted in over 100 patents covering key cell
engineering technologies, including what we believe are the most
widely used methods for therapeutic gene editing currently in
clinical development. Eterna has exclusively in-licensed this
extensive patent portfolio to develop a pipeline of valuable
therapeutic products, which the Company plans to advance both
internally and through strategic partnerships. I look forward to
providing additional information about Eterna’s progress over the
coming weeks.”
About Brooklyn ImmunoTherapeuticsBrooklyn is
focused on developing advanced therapies using state-of-the-art
mRNA cell engineering technology. Brooklyn has multiple
next-generation cell and gene-editing therapies in preclinical
development for various indications. For more information, please
visit www.BrooklynITx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Brooklyn’s business model into a platform company
focused on cellular, gene editing and cytokine programs; (ii)
Brooklyn’s ability to successfully, cost-effectively and
efficiently develop its technology and products; (iii) Brooklyn’s
ability to successfully commence clinical trials of any products on
a timely basis or at all; (iv) Brooklyn’s ability to successfully
fund and manage the growth of its development activities; (v)
Brooklyn’s ability to obtain regulatory approvals of its products
for commercialization; and (vi) uncertainties related to the impact
of the COVID-19 pandemic on the business and financial condition of
Brooklyn, including on the timing and cost of its clinical trials.
You should not rely upon forward-looking statements as predictions
of future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Brooklyn does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Brooklyn’s
actual results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Brooklyn’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Brooklyn’s Annual Report on Form 10-K for the
year ended December 31, 2021, as amended, as well as under similar
headings in Brooklyn’s subsequently filed Quarterly Reports on Form
10-Q and Current Reports on Form 8-K.
Investor Relations
Contact:investors@brooklynitx.com
Media Contact:Jon YuICR
Westwicke475-395-5375BTX-PR@westwicke.com
Brooklyn ImmunoTherapeut... (NASDAQ:BTX)
過去 株価チャート
から 5 2024 まで 6 2024
Brooklyn ImmunoTherapeut... (NASDAQ:BTX)
過去 株価チャート
から 6 2023 まで 6 2024